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1. Introduction
1.1 The marriage of ‘high throughput’ and ‘high content’
While the pharmaceutical industry innovation crisis draws much debate (Kaitin & DiMasi,
2011; Macarron et al., 2011; Munos, 2009; Paul et al., 2010), there remains little consensus on
how to cohesively deliver value throughout the drug development pipeline (Fig. 1). This
chapter considers some of these issues in the context of a growing field for computational
biology: drug discovery high throughput screening (HTS). HTS is the approach of rapidly
studying physical, chemical, biological and genetic perturbations on the scale of of tens of
thousands per day. Today we are faced with ultra-HTS daily screen rates of hundreds of
thousands, in part thanks to the continued development of technologies such as micro-fluidics
(Agresti et al., 2010). As a discovery tool, it traces it roots back over twenty years (An &
Tolliday, 2010), however it is the more recent improvements in cell culture technique - with
the potential for multivariate output such as gene expression - that brings it into the domain of
high content computational biology. With this maturation of cell-based assays we also notice
an increased focus on statistical rigour, analytical integration, and the apparent user-driven
plateau in miniaturisation (Mayr & Bojanic, 2009). Rather than being faced with a continued
improvement in simple assay throughput, these suggest a growing role for more data-rich
high content HTS (hcHTS)1.
Despite the implicit gains, there exists a notable and growing antipathy towards many ‘big
data’ approaches as discovery tools. Much publication has refocused on data quality versus
quantity, with some doubting the impact of high throughput science altogether (Douglas
et al., 2010; Macarron et al., 2011; Mayr & Bojanic, 2009). There persists the very real hurdle
of experimentalists and team leaders struggling with the interpretation, integration, and
decision making based on such data. As a concern routinely witnessed in post-genome era
science, it is doubtful that the blame rests primarily with problem-specific methodology. In
this chapter, the need for screens to bemore decision-centric and transparent across disciplines
is proposed. The aim here is not just to provide the reader with specific tools that are likely to
rapidy become dated, but introduce the scope and opportunities in drug screening science.
1 In this chapter ‘high content’ is used interchangeably with ‘high dimension’, as applied to multiplexed
technologies that produce many descriptors per sample, well or observation. A common example is
gene expression microarrays. ‘High content screening’ is commonly used in the literature to indicate
high content imaging. To avoid confusion here, the high content approach to HTS is referred to as
hcHTS, and high content imaging is referred to as HCI.
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Fig. 1. No single approach is prototypical of drug development. Particularly as a growing
number of therapeutic programmes focus on ‘biologics’ - such as proteins and RNA
inhibitors - versus ‘small molecule’ chemical therapies. However, in general it remains an
arduous, failure prone process of 10-15 years, costing hundreds of millions to billions of US$
(Adams & Brantner, 2006). The pipeline can be described as a task in managing attrition
rates; a process with a very low success rate sometimes beginning with many hundreds of
thousands of chemicals to launch a single successful therapy. The research and development
life of a potential drug might be considered in five phases. The first being the identification,
development and validation of a target for the drug; the most common targets being
G-protein coupled receptors and kinases. The second phase involves the discovery of ‘hit’
chemicals affecting the target, and development of the hits into leads. Hit through to lead
research often begins as high throughput assays, where large libraries of chemicals are
screened for effect and sometimes side-effect. What remains are the development phases of
animal (preclinical) and human (clinical) testing prior to market release and surveillance
(pharmacovigilance).
1.2 The vital role of computational biology
hcHTS provides a unique challenge to the computational biologist more familiar with high
dimension analysis. It increases the analytical demand from the ‘few observations, many
descriptors’ paradigm of small sample multiplex genomics to that of ‘many observations,
many descriptors’. Drug discovery is also gradually devolving its chemo-centric dominance
into an increasingly bio-centric approach. This positions computational biology as a crucial
bridge between complex science and technology, and the challenging decisions that need
be made from the data produced. The melting pot of in vitro (cell-based and biochemical)
biology, cheminformatics, bioinformatics, systems biology, and ‘big data’ analysis requires
broad inter-disciplinary scientific and computational strengths. It affords the computational
biologist the opportunity to become part of a wide ranging science. A practice where
hypotheses and data iteratively refine screens and studies, converging on greater scientific
understanding and defined solutions.
This chapter is divided into two main parts. Section 2 contextualises some of the
challenges and considerations to guide the choice of modelling strategy, whilst section 3
provides a simple predictive toxicology example that builds on these suggestions. Two
traditionally medium throughput multiplex approaches - now increasingly being used in
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higher throughput settings - will be discussed: gene expression and high content imaging
(Bickle, 2010; Zanella et al., 2010). For other promising hcHTS technologies, such as flow
cytometry (Edwards et al., 2009) and label-free methods for real time living cell assessment
(Xie et al., 2009), the reader is referred to the provided citations. High content imaging (HCI)
utilises high resolution multiplex fluorescence microscopy - typically immunofluoresence - to
study cellular architecture and health (Karol Kozak, 2009; Zanella et al., 2010). Its strength as
a tool is the single cell resolution of physiologically relevant endpoints. HCI together with
transcriptomics might be thought of as high content cell and molecular phenotyping. While
gene expression analysis is not typically considered part of phenotypic assays, in the context
of hcHTS where perturbed pathways and their reporter genes are are studied as indicators of
biological process and cell state, it should very much be seen as a proxy of the cell’s molecular
phenotype. An example of where the two approaches have become inextricably linked is RNA
inhibition screens (Karol Kozak, 2009).
2. Modern high throughput drug discovery
2.1 ‘Big data’ analysis paralysis
Not without its critics (Douglas et al., 2010), the ongoing drug discovery mantra has been
one of managing attrition rates by ‘failing early, failing often’. However, the biological and
drugability knowledge around validated targets has remained poor. An often cited FDAwhite
paper of the early post-genome years (FDA, 2004) drewwidespread attention by calling for the
greater use of biomarkers and computational approaches to improve this knowledge. With the
strong political willpower to modernise drug discovery, HTS has continued to gain popularity
as a brute force innovation tool, entering the public domain with resources such as ChemBank
(http://chembank.broadinstitute.org), PubChem (http://pubchem.ncbi.nlm.nih.gov) and
ChEMBL (https://www.ebi.ac.uk/chembldb). Progress has however faced persistent
concerns, with common complaints being poor chemical library design (Gillet, 2008) and that
of decision-makers drowning in data. While chemical library design is beyond the scope of
this chapter, the data concern is one familiar to every high content computational biologist.
A contrasting argument to the suggested deluge of data as the core concern is that the
principal challenge lies with modelling strategy; not the data per se. A case in point might
be made of the much publicised Large Hadron Collider with its daily data quota exceeding 40
terabytes. This represents more data than that managed by a typical computational biology
team and - while still requiring considerable computing resources - remains a manageable
data flow. This is arguably due to well developed theoretical models around which physics
expects the data to behave. In contrast, theoretical and systems biology still suffer from a
paucity of rigorous quantitative models relevant to disease and chemical biology. The ship
may be sinking not because the ocean is large, but because the water is bailed with teaspoons.
What then are the most appropriate strategies? To answer this we first need to appreciate
that the challenge with screening science is less that of providing narrowly focused yes/no
answers. Rather it is more a task of iteratively triaging the optimal options, while managing
the decision-making risk across heterogeneous studies spanning months to years. Though
not a style of research unaccustomed to statisticians and decision analysts, this challenges
computational biology culture with its often data-centric rather than decision-centric and
translational mandates.
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Fig. 2. A useful paradigm for HTS is that of the layers in a ‘modelling onion’, which
emphasises the crucial role of the computational biologist, bridging technology and scientific
decision making. Initial research is often driven by technology modelling: choosing the
optimal biological models, experimental protocols and technologies to provide good data
signal. Data modelling is the remit of computational biology, which might be divided up as a
spectrum of low level data clean-up through to higher level theoretical and systems
modelling. The screening computational biologist needs to balance the merits of providing
detailed results versus fast results; the latter proving useful if they enable the research team
to make real-time decisions and rapidly test hypotheses. In HTS this is often the balance of
primary versus secondary screening strategies. The final, often neglected, layer is decision
modelling. No matter how well the HTS technologists and informaticians consider their
models to be performing, if these don’t explicitly and transparently assist large discovery
teams in making decisions, they are effectively of little use.
2.2 Improving your modelling IQ2
Modern biology retains its distinctive knowledge-driven culture as a science; differentiated
from more mature sciences as being heavily dependent on phenomenological ‘stamp
collecting’. Similar divides manifest in computational biology as low level data collection,
clean-up and mining of bioinformatics versus computational biology modelling. In research
with direct translational and economic goals - such as drug screening - it is helpful to
remember that:
• Science exists to create explanatory and/or predictive models. Cohesive and
comprehensive modelling practice along the entire drug development pipeline is the
mandate of all researchers from in vitro to in silico to the patient.
• All models are wrong, some are useful. Particularly in HTS drug discovery, the
development and use of models should be driven by their utility as transparent, triaging
decision tools, not narrowly focused technological arguments.
• HTS combines three levels of modelling. Technology, data and decision models should be
seen as essential layers in a ‘modelling onion’ (Fig. 2).
There is, of course, no silver bullet to address data rich problems in drug screening.
Notwithstanding, there are general considerations before deciding onmethods to optimise the
screening model (Fig. 3). A few overlapping rules of thumb are suggested here as a measure
of a screen’s IQ2. The test for IQ2 summarises the need for better integration, assay quantitative
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Fig. 3. The above immuno-stained cells - after timed exposure to a toxic chemical - provide a
simple example of the screening model in three parts: technology, data and decision
modelling. Here technology modelling involves the choice of an informative fluorescent
biomarker in an appropriate cell model after an optimal perturbation duration. The data
model might be to infer the lowest concentration at which 10% of cells are statistically
significantly brighter than twice the average baseline fluorescence. This type of model is a
‘lowest dose with an effect’ model, where the combination of statistical and biological
significance define the concentration output. The utility as a decision tool might be to
provide a reproducible relative measure of cytotoxicity across collaborating laboratories
interested in a simple ranking of cytotoxic effect, viz. a robust measure best suited as an
ordinal triage of effect. The aim being hazard identification, with little explicit attention to
risk management and translational or economic impact.
performance, and the decision-making synergies (the squared exponent) which present with
the action-enabling results.
How well does your approach integrate? Integration entails more than just the use of all available
data, but includes the effective integration along the entire flow of data through to knowledge
and scientific wisdom (Fig. 4). This is the central tenet of translational bioinformatics, which
aims to promote free flow of data between the lab and patient (Buchan et al., 2011). Still in the
early stages, translational informatics projects such as Informatics for Integrating Biology and
the Bedside (http://www.i2b2.org) hold much promise for feeding back into HTS.
How quantitative is your approach? The quality of the inference is limited by the quantitative
performance of the screen. Too often it would seem that post hoc analysis attempts to stretch
the assertions made by screening models not fit for purpose. In HTS the primary measures
of interest are dose and time. If, for example, a screening programme is required to predict
a new drug’s safety concerns (‘how toxic?’), these might be framed as one or more of many
dose and time relevant questions. A few translational toxicity concerns are listed below:
• The concentration at which a percentage of the population begin to experience an effect.
• The concentration at which the risk of rare (unpredictable) adverse effects becomes too
great.
• The extent of pathology after a set dose and time exposure.
• The optimal dosing schedule to minimise toxicity without significant loss of efficacy.
• Chronic affects - such as bioaccumulation - less easily extrapolated from acute and
sub-acute testing.
319igh Content and Throughput Drug Discovery
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Fig. 4. The flow of data into results and decisions reflects the well described flow of
information into knowledge and wisdom. Bioinformatics began, in part, as a field to address
data integration concerns (Searls, 2010). Today the integration of technologies, laboratories
and heterogeneous databases is common practice, and remains vibrant with emerging
resources such as cloud computing (Mak, 2011; Schadt et al., 2010). Less well practised is the
routine and formal integration of results beyond simple score-based meta-analyses. Bayesian
computation promises more formal approaches to update results and incorporate prior
information, yet advanced statistical treatment remains underutilised in modern HCS (Malo
et al., 2006). Again, the importance of assisting with decision making deserves greater
attention. Modelling approaches need be transparent enough to allow a diverse community
of scientists to easily communicate and understand the analytical assumptions and
limitations.
A role of the screening computational biologist should be seen as providing reliable
quantitative measures of concentration and time to hypotheses/questions; not just the
provision of IC50 or EC50 values per variable. The concern, for example, is not the reliable
measure of gene expression and the confidence around these measures per se. Rather, it’s the
transformation of these values into measures of concentration and time, and the confidence
around these measures.
Three quantitative concerns often deserving better consideration are suggested:
• The first is the signal-to-noise ratio (Fig. 5A), commonly measured as Z = 1−
3(σˆp+σˆn)
|µˆp−µˆn |
, for
positive and negative controls p and n respectively. A Z-score greater than 0.5 is typically
accepted to suggest a good assay. The Z-score is a narrowly focused measurement aimed
at single-plex assays, which is not robust and assumes data normality. It also does not take
into account the performance impact on decision making.
• A second concern is dynamic range. Not all cell models or technologies provide an
adequate dynamic range in which drug effects over wide concentration ranges can reliably
be measured by a broad spectrum of markers exhibiting near-linear correlation with the
effects they proxy. A well known example of this is the poor dynamic performance
of gene expression microarrays demonstrated by the Microarray Quality Control project
(MAQC Consortium et al., 2006). The screening computational biologist needs to clearly
demonstrate the adequate dynamic performance of their data prior to establishing any
routine screening.
• The third and final consideration can be broadly defined as that of information
resolution. Screens and their follow-up secondary screens/studies need to define clear
goals of improving concentration and time sampling density to ensure accurate and
sufficiently precise quantitative assertions. The results also need to be presented to
the decision-making team at an optimal resolution to be informative without being
overwhelming (Fig. 5B - 5D).
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Fig. 5. (A) quantitative PCR measurement of gene expression remains the most common gold
standard for assessing gene expression without the dynamic limitations of nucleic acid
hybridisation technologies, such as gene expression microarrays. However, as can be seen in
this well controlled example of highly replicated measurements for a single gene across
several compounds, achieving repeated in vitro measurement within 1 CT unit remains a
challenge. Assuming near optimal reaction efficiency, the CT scale approaches log2,
indicating the cost and time challenge of adequate replication to confidently discern the
doubling of a gene’s expression under screening conditions. (B-D) The resolution at which it
is optimal to present results affects the design and/or execution of the data modelling.
Figure B provides a detailed trace of five genes perturbed by a compound in a secondary
screen. While being detailed, it is ineffective at answering ‘at what dose?’ and quickly
becomes intractable in terms of technical cost and analysis when comparing multiple
compounds. Figure C partly resolves this by presenting the results as bars beginning at the
lowest concentration at which the answer to the question becomes true. Figure D presents
this information for the same genes, comparing tested compounds, numerically providing
the concentrations and displaying the statistical confidence in the results as being
proportional to the bubble size. Here we see that drug B behaves most similarly to drug A,
but at a 5-fold higher concentration (lower potency). It would seem from the screen that we
can be fairly confident that drug C behaves differently from drugs A and B.
321igh Content and Throughput Drug Discovery
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Fig. 6. Careful consideration need always be given to the actionability of screening methods
used. If, for example, compound A clusters (or classifies) together with a prototypical
compound in cluster A, while compound B clusters together with another prototype in
cluster B, does this provide sufficient information to prioritise compound A with a defined
dose and time dependent confidence? Similarly with pathway-driven approaches. If
compound A does not up-regulate genes H and J at low concentrations, how does this
translate into dose and time dependent effects for the purposes of screen prioritisation?
How actionable is your approach? The most important consideration is how effective the
screening strategy is at enabling the team tomake informed decisions that lead to clear actions
where the utility, cost and risk attached to those actions are understood. These can again be
considered at the technology, data and decision modelling levels.
Technologist bias will routinely be towards increasing technology complexity within time and
cost restraints. However, increased complexity needs to translate into improved actionability.
The debate on simple cell culture techniques replaced by the earlier use of lower throughput
three-dimensional approaches (Fernandes et al., 2009) highlights this concern. Complex in
vitro approaches run the risk of compromised data reproducibility. If reduced reproducibility
and cost of technology complexity outweigh potential gains in insight, the technological
improvements and necessary data modelling changes need be questioned.
The over-reliance on exploratory bioinformatics without clear quantitative questions,
hypotheses and follow up is arguably core to current innovation failures (Fig. 6). Three pillars
of result significance enable the rational implementation of screens:
• The first is statistical significance, which has traditionally played a minor role within
single-plex HCS (Karol Kozak, 2009; Malo et al., 2006).
• Not to be confused with statistical significance is biological significance. A differentially
expressed gene defined purely in terms of statistical confidence above baseline needn’t
represent its biological relevance as a useful marker to elucidate mechanism or enable clear
actions based on screening questions.
• The economic argument forms the final pillar, where cost is considered together with utility
(Swamidass et al., 2010).
Bayesian methods provide a useful framework to formally work with these different notions
of importance, whilst also enabling the use of external data - such as cheminformatics and
322 Systems and Computational Biology – Molecular and Cellular Experimental S stems
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Fig. 7. Common cheminformatics practice is to define descriptors of structure and
physiochemical properties in order to position a compound in chemical space. If the purpose
of bioinformatics is not only to define molecular and cellular phenotype patterns and
mechanisms, then the role of the screening computational biologist effectively becomes a
collaborative counterpart to the cheminformatician, defining biological descriptors that are
not merely useful as biologically predictive or mechanistic markers, but can be mapped to
chemical descriptors in order to define structure-activity relationships (SAR) for rational
drug design.
pharmacoeconomics - to establish meaningful priors. However Bayesian analysis appears
notably absent in routine published practice (Klon, 2009; Nidhi et al., 2006). Computational
limitations seem less likely than the poor understanding surrounding the use of these
methods. The need for model understanding and transparency by the entire decision making
team is paramount. So until formal frameworks can meet this need, we are left to rely on
simpler approaches, some of which are discussed later in this chapter.
Finally, it might be argued that screening methods should ultimately strive not to provide
a ‘post-mortem’ of results but actively assist the discovery team to design better therapies.
If, for example, a screen has been developed to predict a spectrum of toxicities from tested
chemicals, it should not only accurately identify the correct toxicities, but also their dose-time
properties while guiding the chemists on how to alter the compound structures to improve
their safety profiles. This re-emphasises the argument for generalist computational biologists
in HTS who are able to collaborate with the chemical design and cheminformatics teams,
identifying actionable structure-activity relationships (Fig. 7).
3. ‘Next generation’ drug screening
The title above has deliberately been borrowed from the same description applied to second
generation nucleic acid sequencing technologies. It is used in part to stress the increasingly
high content flavour of HCS, but also the need for a new screening paradigm focused on
a cohesive, transparent and actionable modelling practice. Drawing from real data, this
323igh Content and Throughput Drug Discovery
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section demonstrates how a screen for genotoxicity might be created using currently available
software. The aim is to present how simple rules, weights and thresholds can be used as one
approach to create screens not only with good performance characteristics but which can be
easily understood and acted on by all team members.
3.1 Rules, weights and thresholds
Cheminformatics has routinely utilisedmachine-driven pattern recognition to distil large data
sets into rule-based models as a form of ‘human readable’ modelling, or rules of thumb, to
predict drug properties. A well known example applicable to ADME is Lipinski’s Rule of
Five, which assesses how likely it is that a chemical will be orally active. To pass Lipinski’s
rule, a chemical is limited to violating no more than one criterion:
• Less than or equal to five hydrogen bond donors.
• Less than or equal to ten hydrogen bond acceptors.
• Less than or equal to 500 daltons in molecular weight.
• An octanol-water partition coefficient log P less than or equal to 5
In a similar vein, standard bioinformatics methods can be distilled into combinations of
rules, creating such models. These can be tested, refined and understood by non-specialists
across the drug discovery team (Fig. 8), with biological and decision-relevant significance
better ensured by applying transparent weights and thresholds (Fig. 9). As a consequence
of increased computing power and data set size, it seems likely that rule-based approaches
will grow in popularity as a tractable modelling strategy. Rule-based modelling has already
proven popular in systems biology, where unmanageable lists of differential equations have
yielded to agent-based rules of interaction used to drive simulations (Barnes, 2010; Krakauer
et al., 2011; Yoav Shoham, 2009). As a methodological approach, rule-based modelling
provides a natural bridge for team-driven hypothesis generation and the maturation of
generalities for mechanistic and screening biology treated as information science. A particular
benefit of rule-based models in screening is that it also allows for the seamless integration of
multiple data types. A model might be a collection of rules from multiple cell culture models,
multiple time scales, and multiple technologies such as quantitative PCR, HCI, and classical
cytometry. Collectively, all of these benefits ensure a high IQ2 for rule-based models.
3.2 Screening with HT-StreamTM
In vitro drug safety screening currently falls within the domain of what are typically
medium throughput models aimed at predicting drug absorption, distribution, metabolism
and excretion (Ekins et al., 2005). These models are collectively referred to as predictive
ADME. Combinatorial chemistry and the shift of ADME to early stage discovery have both
significantly improved our ability to design efficacious pharmaceuticals. This has left drug
toxicity as an important bottleneck contributing to the innovation crisis, and has prompted its
shift to earlier ‘off target’ cell screens. Whilst born out of lower throughput toxicogenomics
(Van Hummelen & Sasaki, 2010), this shift of high content application to high throughput
screening requires new methodology and software.
Fig. 10 provides an example of two established DNA damage and stress markers tested
on the hepaRG® human liver cell co-culture (Guguen-Guillouzo & Guillouzo, 2010) using
quantitative PCR. Microfluidic ‘lab-on-a-chip’ improvements have enabled cost-effective,
high throughput quantitative PCR (Stedtfeld et al., 2008); dramatically improving the
scalability of this gold-standard technology as a stand-alone tool or in conjunction with
324 Systems and Computational Biology – Molecular and Cellular Experimental S stems
www.intechopen.com
High Content and Throughput Drug Discovery 11
Fig. 8. The apoptosis pathway, as represented above, is commonly used to predict drug
safety concerns. A typical bioinformatics approach in a high dimension setting might be to
search for apoptosis gene enrichment. Gene set enrichment based on established pathways
or ontologies is a rough exploratory tool that translates poorly into a setting where a precise
dose-response relationship is required. Using unguided machine learning, literature mining
and expert knowledge, complex pathways can be stripped down to collections of rules able
to be refined over time and combined to form rule-based models. An example of a rule-based
model might be ‘clinically significant human apoptosis when at least one, but no greater than
four of the following gene ratios hold true. . . ’. In a dose-response setting, the lowest
concentration at which the rule holds true is called, as a ‘lowest dose with an effect’ model.
other high content methods such as HCI. While it remains traditional to begin testing gene
expression at cell cytotoxicity IC50 concentrations, these do not represent physiologically
appropriate dosings. As suggested in the data correlations of Fig. 11, HCI allows for
mechanistically relevant concentrations to refine classic viability assays in the absence of
reliable human data; and discover transcriptomic biomarkers for use in rule-based models.
Once the models have been developed, HT-StreamTM (www.ht-stream.com,
www.simugen-global.com) proves useful as online collaborative software that presents
the results in a decision-focused manner (Fig. 12). All submitted screening data undergoes
automated quality control (Fig. 10A), prior to the inference of the lowest concentration
at which each rule becomes true. HT-StreamTM uses the derived concentrations, together
with weights and thresholds to help prioritise compounds, visualise results, and compare
models (Fig. 13). Easy-to-use software such as this helps make it possible for teams to create
‘ecosystems’ of applications, rules and models; continuously refining them as collective
interdisciplinary knowledge grows with transparent, decision-centric screens.
325igh Content and Throughput Drug Discovery
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Fig. 9. The above plots represents the output for two ‘lowest dose with an effect’ models for
five tested compounds. The aim here is to rank compounds from highest to lowest toxicity,
viz. prioritise those presenting with toxicity at lower concentrations. The darker a
compound’s label, the higher it is prioritised. The x-axes represent increasing microMolar
concentrations of the compounds, with bars representing 95% confidence intervals. (A) Here
we observe the simplest prioritisation: drug A demonstrates high potency (from model A)
and so is ranked first. The benefit of presenting data as concentration values, and the
statistical confidence around those values, is evident. While drug A is prioritised over drug
B, their confidence intervals overlap, suggesting insufficient statistical evidence to support
the ranking. (B) The same results are plotted, but with a threshold added to drug B. In this
example, drug B has prior information regarding its therapeutic efficacy. The discovery team
have decided that any toxicity called above a certain threshold will be of little consequence,
as it is unlikely to be reached at therapeutic concentrations. By including this threshold, drug
B is de-prioritised. (C) The previous rankings assume an equal weighting of the two models.
In reality this is rarely the case. If model A represents the drug’s carcinogenic potential,
whilst model B represents a low-grade safety concern, then model A requires a greater
weighting in the global prioritisation. Here drugs D and E switch positions as model B is
assigned a low weighting. Thresholds and weights ensure transparent assumptions of
biological relevance. With the inclusion of prototypical compounds in the test rankings,
transparent weights, thresholds, and statistical significance enable the team to collectively
make informed, defensible decisions.
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Fig. 10. Genotoxicity biomarkers in hepaRG® viewed using the online tools provided by
SimuGen. (A) The doubling of CDKN1A’s expression with high dose cyclophosphamide.
The x-axis represents increasing compound concentration, while each tick in the y-axis
represents a CT unit; a drop in one unit thus representing a doubling in gene expression. The
analysis tools provide robust automated quality control, in this case identifying two
measurements believed to be outliers in bold. (B) SimuGen’s biomarker discovery tools
provide a reference database for over 22,000 genes tested across multiple chemical
perturbations in hepaRG®. The above result for GADD45A has identified its most strongly
correlated toxic biomarkers, and plotted their first two principal components. GADD45A is
highlighted with an arrow and can be seen to be closely clustered with, and enriching for,
known genotoxic biomarkers.
327igh Content and Throughput Drug Discovery
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Fig. 11. HCI allows the standardisation of compound concentrations using mechanistic
criteria. This correlation plot demonstrates strong correlation (dark squares: Pearson >0.8)
and anti-correlation (light squares: Pearson<-08) between known hepatotoxic biomarkers
and microscopic phenotypes. The gene expression profile for each compound is measured at
the lowest concentration at which any HCI phenotype emerges. Considering drop in
mitochondrial mass and potential as a joint phenotype (highlighted) shows strong
association with with stress, metabolic and cirrhosis markers. Strong correlations such as
these indicate the compatibility of the approaches and the ability to used joint HCI and gene
expression data in rule-based models.
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Fig. 12. The right-hand side plot traces the paths of GADD45A and CDKN1A over almost 50
chemicals as their concentrations increase. The black paths represent known genotoxic
drugs. It can be seen that there is a ‘golden ratio’ for the two genes between the dotted lines.
Most compounds fall below, whilst non-genotoxic compounds typically present above.
HT-StreamTM allows such rules to be entered.
Fig. 13. Using the weights and thresholds, all tested compounds are ranked in HT-StreamTM.
Any model with a positive result has its results plotted, and contrasted to similar behaving
compounds, as described in Fig. 9. A principal components plot, using all models, is also
provided to allow the computational biologist and chemist to identify overall patterns that
might be related back to chemical structure.
329igh Content and Throughput Drug Discovery
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